[{"id":"bd5e2f13-5c03-4779-a52a-14cdbde4fbf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00603668","created_at":"2021-01-18T02:14:23.258Z","updated_at":"2024-07-02T16:36:26.290Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL","source_id_and_acronym":"NCT00603668","lead_sponsor":"Gilead Sciences","biomarkers":" CD74","pipe":"","alterations":" ","tags":["CD74"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milatuzumab (IMMU-115)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2021-08-16"}]